Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Raltitrexed + Nab-Paclitaxel in Advanced Pancreatic Cancer
NCT04581876Phase 2Unknown
- Sponsor
- Fudan University
- Start
- Nov 2019
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of raltitrexed in pancreatic cancer (PC), sponsored by Fudan University. Primary endpoint: Progression Free Survival up to 36 months. Status: unknown.
02
Drugs
raltitrexed
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT04581876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04581876.